ANEUVO is a pioneering bioelectronic medical device company focused on developing advanced technologies and therapies for patients with diseases and injuries that have not responded to conventional medical approaches. Founded in 2016 by leading neuroengineering experts, the company blends world-class research with entrepreneurial vision to deliver breakthrough neuromodulation solutions for individuals with limited or no therapeutic options.
The company’s flagship innovation is the ExaStim® Stimulation System, an FDA-cleared and CE Mark-approved non-invasive device specifically designed to improve hand sensation and strength in individuals living with chronic spinal cord injuries (SCI). Recognized as a Breakthrough Device by the U.S. Food and Drug Administration, ExaStim utilizes a flexible 16-channel multi-electrode array to deliver transcutaneous spinal stimulation (TSS) without the risks, recovery downtime, or complications associated with surgical implants. When paired with standard rehabilitation, the device re-engages the nervous system to reactivate neural circuitries, supporting meaningful neuroplasticity and functional recovery.
Through MellingMedical’s established contract vehicles, ANEUVO’s technology is readily accessible to federal healthcare providers serving America’s veterans and active-duty military personnel. Because ExaStim is lightweight, portable, and controlled via an intuitive touchscreen app-based platform, it empowers clinicians to seamlessly transition veteran rehabilitation from the VA or DoD clinical setting directly into the patient’s home. This provides our nation’s heroes with a highly customizable, non-surgical pathway to regain their independence, accomplish their therapy goals, and achieve lasting improvements in their daily quality of life.